lundi 30 septembre 2019

Onco Actu du 30 septembre 2019 - Spécial ESMO

5.6.10 ESMO - VESSIE

Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers [Fierce Biotech]

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer [Seattle Genetics]

Seattle Genetics' armed antibody scores high in frontline bladder cancer, taking center stage at ESMO [EndPoints]


The Use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials [ESMO]


J&J's Erleada misses survival mark, but execs see reason to cheer [Fierce Pharma]

Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide) [Johnson&Johnson]

5.6.14 ESMO - OVAIRE

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer [Merck]

AstraZeneca, Merck strengthen lead in PARP drug class [Biopharma Dive]

AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win [Fierce Pharma]

AbbVie’s PARP veliparib finally gets a win, but can it compete? [Fierce Biotech]

Lynparza improved the time women lived without disease progression to 22 months in the broad population and to 37 months in HRD-positive patients as 1st-line maintenance treatment with bevacizumab for newly-diagnosed advanced ovarian cancer [AstraZeneca]

Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer [GSK]

Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced Ovarian Cancer [ESMO]

Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial: Adding Olaparib to Bevacizumab Maintenance Demonstrates Substantial Clinical Benefit in Newly Diagnosed Advanced Ovarian Cancer [ESMO]

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use [Reuters]

PRIMA vs PAOLA: GSK and Merck/AstraZeneca square off in a high-profile PARP showdown at ESMO [ESMO]

Incorporating Veliparib into Chemotherapy and Continuing with Veliparib Maintenance Significantly Improved PFS in Newly Diagnosed High-Grade Serous Ovarian Cancer [ESMO]

5.6.15 ESMO - VADS

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) [GSK]


First-Line Pembrolizumab Versus Chemotherapy in Patients with Advanced G/GEJ Cancer Demonstrates Similar Survival and HRQoL [ESMO]

5.6.17 ESMO - FOIE

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma [Roche]

Bristol-Myers Squibb's Opdivo couldn't topple Nexavar in HCC — but will better safety profile win over physicians? [EndPoints]

Nivolumab Challenges Sorafenib as First-line Treatment in Advanced HCC [ESMO]


Researchers Identify Possible Methylation Signature for Brain Metastases of Lung Cancer [Genome Web]

Treatment Tailored by Molecular Gene Expression Analysis Fails to Improve Outcome in Patients with CUP [ESMO]


Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit [Fierce Pharma]

The EPIPHANY Index Assesses Risk of Short-Term Serious Complications in Patients with Cancer and Pulmonary Embolism [ESMO]


Secondary Resectability Improved with Induction Chemotherapy in Locally Advanced Pancreatic Cancer [ESMO]


Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa [Roche]

Blood Test Can Replace Invasive Biopsy for More Patients with Lung Cancer [ESMO]

New blood test capable of detecting multiple types of cancer [Dana-Farber Cancer Institute]

New blood test could detect more than 20 types of cancer [The Telegraph]

ctDNA From Patients with Colon Cancer Is Indicative of Outcome Following 3 Versus 6 Months of Oxaliplatin-Based Adjuvant Treatment [ESMO]


Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer [Bayer]


Amgen KRAS colon cancer data disappoints [Fierce Biotech]

Colon cancer proves tougher target for Amgen's KRAS drug [Biopharma Dive]

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019 [Amgen]

Amgen isn’t wowing ESMO with the latest KRAS G12C update — but maybe there are more important issues at stake [EndPoints]

Targeted Amgen drug has low response rate in colon cancer in study [Reuters]


Mesothelioma Trial Suggests Immunotherapy as an Alternative to Chemotherapy [ESMO]


Lilly's RET drug shrinks more than half of rare thyroid cancers [Fierce Biotech]

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers [Lilly]

LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer [ESMO]


Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress [Merck]

Molecular Classification Is Prognostic of Adjuvant Treatment Benefit in Patients with High-Risk Endometrial Cancer [ESMO]


Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO [EndPoints]

Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer [BMS]

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study [ESMO]

ESMO Congress 2019 Spotlight on Leptomeningeal Metastases [ESMO]

Ceritinib Targets Brain Metastases in Patients with ALK-positive NSCLC [ESMO]

tTMB Is Not Established as a Marker for Pembrolizumab Efficacy in NSCLC [ESMO]


AstraZeneca eyes payer boost with Tagrisso's latest survival win [Fierce Pharma]

Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years [AstraZeneca]

AstraZeneca heralds Tagrisso's OS lead over old TKIs in lung cancer niche [EndPoints]

Final FLAURA Results Demonstrate Overall Survival Benefit with Osimertinib Over TKIs in Advanced NSCLC [ESMO]


Is Roche's new Tecentriq data a match for Keytruda's 'lead and loyalty' in lung cancer? [Fierce Pharma]

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer [Roche]


Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer [Roche]


Adjuvant Treatment with Opdivo (nivolumab) Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients [BMS]

Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma [BMS]

Bristol-Myers Squibb boasts impressive 5-year melanoma OS data on Opdivo/Yervoy combo, though it still can't pinpoint who should take it [EndPoints]

Nivolumab Combined with Ipilimumab or Alone Outperforms Ipilimumab at 5 Years in Advanced Melanoma [ESMO]

Half of patients surviving 'untreatable' skin cancer following treatment breakthrough, study finds [The Telegraph]

Adjuvant Nivolumab Continues to Provide Superior Recurrence-Free Survival Benefit Over Ipilimumab at 3 Years in Patients with Resected Stage III or IV Melanoma [ESMO]

New treatment extends life of advanced melanoma patients [The Guardian]

5.6.6 ESMO - SEIN

Merck's Keytruda posts first-in-class victory in pre-surgery breast cancer [Fierce Pharma]

Significant PFS Benefit Observed with Veliparib plus Carboplatin and Paclitaxel in Patients with Advanced HER2-negative Breast Cancer and BRCA1/2 Mutations [ESMO]


G1 shares data on significant increase in breast cancer survival [Fierce Biotech]

Merck learns from Keytruda's monotherapy miss in triple-negative breast cancer [Fierce Pharma]

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC) [Merck]

Merck's top cancer team basks in the warm light of positive Keytruda data from a landmark study for hard-to-treat breast cancer [EndPoints]

Adding Pembrolizumab to Neoadjuvant Chemotherapy Improves Outcome in Early TNBC [ESMO]


Novartis, Lilly drugs set new survival bar in breast cancer [Biopharma Dive]

Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients [Novartis]

Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study [Lilly]

Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises — but can they actually beat Pfizer's blockbuster? [EndPoints]


Gut Microbiota May Support an Immune Tolerant Profile That Affects Ipilimumab Activity [ESMO]


Pfizer eyes commercial scale-up as Array colorectal cancer combo hits its marks [Fierce Pharma]

Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer [Pfizer]

Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer [Seattle Genetics]

Dual HER2 Blockade in Patients With HER2-Amplified Metastatic Colorectal Cancer [ESMO]